These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38099569)

  • 21. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.
    Vlot MC; Klink DT; den Heijer M; Blankenstein MA; Rotteveel J; Heijboer AC
    Bone; 2017 Feb; 95():11-19. PubMed ID: 27845262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transition memories: experiences of trans adult women with hormone therapy and their beliefs on the usage of hormone blockers to suppress puberty.
    Giovanardi G; Morales P; Mirabella M; Fortunato A; Chianura L; Speranza AM; Lingiardi V
    J Endocrinol Invest; 2019 Oct; 42(10):1231-1240. PubMed ID: 30953318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth in Transgender/Gender-Diverse Youth in the First Year of Treatment With Gonadotropin-Releasing Hormone Agonists.
    Schulmeister C; Millington K; Kaufman M; Finlayson C; Kennedy JO; Garofalo R; Chan YM; Rosenthal SM
    J Adolesc Health; 2022 Jan; 70(1):108-113. PubMed ID: 34315674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Adrenal Androgens During Puberty Suppression and Gender-Affirming Hormone Treatment in Adolescents With Gender Dysphoria.
    Schagen SEE; Lustenhouwer P; Cohen-Kettenis PT; Delemarre-van de Waal HA; Hannema SE
    J Sex Med; 2018 Sep; 15(9):1357-1363. PubMed ID: 30224022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth, growth potential, and influences on adult height in the transgender and gender-diverse population.
    Roberts SA; Carswell JM
    Andrology; 2021 Nov; 9(6):1679-1688. PubMed ID: 33969625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of Bone Mass Accrual in Transgender and Gender Diverse Youth Undergoing Pubertal Suppression Therapy.
    Roberge S; Roberge T; Corathers S; Nasomyont N
    J Clin Densitom; 2024; 27(3):101505. PubMed ID: 38936233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Sex Steroid Therapy Without Progestin or GnRH Agonist for Gonadal Suppression in Adult Transgender Patients.
    Pappas II; Craig WY; Spratt LV; Spratt DI
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1290-e1300. PubMed ID: 33247919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation.
    Turban JL; King D; Carswell JM; Keuroghlian AS
    Pediatrics; 2020 Feb; 145(2):. PubMed ID: 31974216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria.
    Stoffers IE; de Vries MC; Hannema SE
    J Sex Med; 2019 Sep; 16(9):1459-1468. PubMed ID: 31405768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychosocial Characteristics of Transgender Youth Seeking Gender-Affirming Medical Treatment: Baseline Findings From the Trans Youth Care Study.
    Chen D; Abrams M; Clark L; Ehrensaft D; Tishelman AC; Chan YM; Garofalo R; Olson-Kennedy J; Rosenthal SM; Hidalgo MA
    J Adolesc Health; 2021 Jun; 68(6):1104-1111. PubMed ID: 32839079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
    Magiakou MA; Manousaki D; Papadaki M; Hadjidakis D; Levidou G; Vakaki M; Papaefstathiou A; Lalioti N; Kanaka-Gantenbein C; Piaditis G; Chrousos GP; Dacou-Voutetakis C
    J Clin Endocrinol Metab; 2010 Jan; 95(1):109-17. PubMed ID: 19897682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of juvenile gender dysphoria.
    Hembree WC
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):559-64. PubMed ID: 24468758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.
    Hembree WC; Cohen-Kettenis PT; Gooren L; Hannema SE; Meyer WJ; Murad MH; Rosenthal SM; Safer JD; Tangpricha V; T'Sjoen GG
    J Clin Endocrinol Metab; 2017 Nov; 102(11):3869-3903. PubMed ID: 28945902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.